의료기기 CRO 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the medical device cRO market size is expected to increase from USD 11.21 billion in 2025 to USD 11.91 billion in 2026 and reach USD 16.82 billion by 2031, growing at a CAGR of 7.14% over 2026-2031.

This report is Segmented by Scale of Operation (Preclinical/Testing, Clinical), Service Type (Clinical Monitoring, Trial Management, Data Management, Regulatory & Medical Affairs, Medical Writing, Patient Recruitment, Pharmacovigilance, and More), Device Class (MedTech, Diagnostic, Handheld, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Medical Device CRO Market Trends and Insights

Outsourcing Intensifies as Device Trials Grow in Volume and Complexity

The medical device CRO market is gaining from a clinical evidence model that now stretches far beyond premarket submission, because post-market surveillance and PMCF are continuous obligations rather than one-time activities. MDCG 2025-10 states that PMS must actively gather and analyze data throughout the life of the device, and that this information must feed back into risk management, clinical evaluation, technical documentation, and corrective action processes. That requirement makes it harder for manufacturers to keep all regulatory, biostatistics, monitoring, and reporting tasks inside their own teams, especially when higher-risk products also require structured reports and ongoing updates.

The medical device CRO market therefore benefits from recurring work on legacy products as well as new launches, since older devices moving into newer frameworks can reopen evidence gaps and trigger fresh outsourcing mandates. Medpace reported full-year 2025 revenue of USD 2,530.2 million, up 20%, and guided for USD 2.755 billion to USD 2.855 billion in 2026, which supports the view that outsourcing demand remained healthy across the broader development services base.

EU MDR/IVDR Evidence and PMCF Requirements Expand Demand

MDCG 2025-10 makes the PMS system an integral part of the quality management system, which means clinical evidence work now sits inside a continuous compliance loop instead of a standalone filing exercise. The guidance also states that a PMCF or PMPF plan must be included within the PMS plan, or the manufacturer must justify why that activity is not applicable. Findings from PMCF and PMPF then have to update clinical or performance evaluation, benefit-risk assessment, labeling, technical documentation, and other ongoing compliance records. In the medical device CRO market, that structure increases demand for monitoring, data management, medical writing, vigilance support, and regulatory maintenance because sponsors must keep evidence current after launch and not only before approval. Providers that can combine real-world evidence capabilities with documentation workflows are better positioned as sponsors transfer more of this work outside internal teams that are already stretched by MDR and IVDR obligations.

Notified Body Capacity Bottlenecks Elongate EU Certifications

Notified Body capacity remains one of the clearest timing risks for the medical device CRO market in Europe because certification flow still lags the volume of work moving through MDR and IVDR pathways. MedTech Europe has described notified bodies as a regulatory bottleneck, and that framing aligns with the sustained pressure on sponsors that need approvals, renewals, and evidence updates under tighter rules. When certification timing slips, milestone-linked contracts can delay revenue recognition for CROs even if clinical or documentation work has already been completed. This does not remove demand from the medical device CRO market, but it does make European delivery schedules harder to predict and increases the value of providers that can combine clinical work with close regulatory coordination. In practical terms, the bottleneck shifts competition toward firms that can manage backlog risk, sequence workstreams carefully, and maintain sponsor confidence during long review cycles.

Other drivers and restraints analyzed in the detailed report include:

1. FDA Cybersecurity Requirements and QMSR Alignment Elevate Software Validation and Cyber Testing Needs
2. Decentralized Trial Adoption in Devices Increases DHT/eClinical and Remote-Operations Outsourcing
3. DCT Patient Recruitment, Tech Access, and Data Governance Hurdles Slow Study Execution

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Clinical services held 58.46% of the medical device CRO market share in 2025, and the same segment is projected to grow at a 7.67% CAGR through 2031. This lead position reflects more than simple trial volume, because manufacturers now face clinical obligations that continue into the post-market period and feed back into risk management and technical documentation. MDCG 2025-10 makes that continuity explicit by treating PMS as an active, ongoing system that must update benefit-risk assessment, clinical evaluation, and corrective actions throughout the device lifetime. For the medical device CRO market, that means clinical work is no longer concentrated only around the first submission, since PMCF and related evidence maintenance extend activity well after launch. The result is a larger and more durable outsourcing pool for sponsors with Class IIb, Class III, implantable, and software-heavy products that cannot support these tasks internally at the required pace.

Preclinical and testing services remain smaller within the medical device CRO market, yet they are becoming more strategically important because they sit upstream of many later regulatory and clinical decisions. Device sponsors still need biological evaluation plans, chemical characterization, toxicological assessments, and gap analyses that align with current regulatory expectations rather than older approval assumptions. Labcorp's stated biocompatibility offering shows how these services already cover ISO 10993 testing, chemical characterization, toxicological risk assessment, and support for legacy-device gap reviews tied to current regulatory standards. This keeps the medical device CRO industry dependent on testing providers that can connect bench work to submission strategy, rather than acting only as isolated laboratories at the start of development.

Geography Analysis

North America held 45.34% of the medical device CRO market share in 2025, which made it the largest regional contributor. The United States accounts for most of this position because the regulatory calendar compressed several compliance demands into a short period, especially through QMSR implementation and updated cybersecurity expectations. QMSR now incorporates ISO 13485:2016 by reference, and it also keeps FDA-specific record controls in place, which means manufacturers must manage harmonization without assuming that ISO certification alone replaces FDA inspection or documentation duties. Many sponsors are filling this gap through outsourcing rather than by relying only on internal QA and RA hiring, which helps sustain the North American medical device CRO market even in a more disciplined spending environment. This makes the region the clearest example of how regulation can expand outsourcing demand through compliance complexity rather than through trial volume alone.

Europe remains the second-largest regional cluster in the medical device CRO market, and it is the geography where regulation most directly reshapes the service mix. MDR and IVDR have pushed more post-market evidence, documentation maintenance, and notified body interaction into the operating model, which increases dependence on CROs that can combine clinical and regulatory work. At the same time, notified body bottlenecks continue to complicate timing, which means CRO demand stays strong even while contract conversion and milestone pacing become harder to predict. This leaves Europe as a region with structural demand strength in the medical device CRO market, but also with more visible revenue-timing risk than North America.

Asia-Pacific is forecast to record the fastest 8.32% CAGR in the medical device CRO market size through 2031. The region benefits from expanding device development activity, but local regulatory pathways still make on-the-ground capability important rather than optional. PMDA maintains formal clinical trial notification and consultation structures for medical devices, and those processes reinforce the need for localized regulatory handling rather than a single global template. This supports demand in the medical device CRO market for providers that can combine regional site access, language support, and regulator-facing execution in Japan and neighboring markets. China and India are also broadening the future demand base as domestic manufacturing pipelines create more clinical and regulatory work that sponsors may prefer to outsource. South Korea adds to this regional appeal because a more efficient approval environment can support hybrid trial models and broader regional study footprints. Middle East and Africa, along with South America, remain smaller in the medical device CRO market, yet multinational registration programs in GCC countries, Brazil, and Argentina still create room for international providers with local operating reach.

1. Avania
2. BSI Group
3. Charles River
4. ClinChoice
5. CROMSOURCE
6. Emergo by UL
7. Eurofins
8. ICON
9. Intertek
10. IQVIA
11. LabCorp
12. MCRA
13. MedPace
14. NAMSA
15. Nelson Labs
16. Parexel International
17. Premier Research
18. ProPharma Group
19. Qserve Group
20. RQM+
21. SGS
22. Thermo Fisher Scientific
23. TUV SUD
24. Veranex
25. WuXi App Tec

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Outsourcing Intensifies as Device Trials Grow in Volume and Complexity
  • 4.2.2 EU MDR/IVDR Evidence and PMCF Requirements Expand Demand for Clinical, Regulatory, and Testing Services
  • 4.2.3 FDA Cybersecurity Requirements and QMSR Alignment Elevate Software Validation and Cyber Testing Needs
  • 4.2.4 Decentralized Trial Adoption in Devices Increases DHT/Eclinical and Remote-Operations Outsourcing
  • 4.2.5 Cross-Border Data Transfer Constraints Drive Privacy Engineering and Data-Residency CRO Services
• 4.3 Market Restraints
  • 4.3.1 Notified Body Capacity Bottlenecks Elongate EU Certifications and Add Planning Uncertainty
  • 4.3.2 DCT Patient Recruitment, Tech Access, and Data Governance Hurdles Slow Study Execution
  • 4.3.3 Cybersecurity SBOM/Patching Obligations Add Recurring QA/RA and Revalidation Burden
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Scale of Operation
  • 5.1.1 Preclinical/Testing
  • 5.1.2 Clinical
• 5.2 By Service Type
  • 5.2.1 Clinical Monitoring
  • 5.2.2 Clinical Trial Management
  • 5.2.3 Data Management & Biostatistics
  • 5.2.4 Regulatory & Medical Affairs
  • 5.2.5 Medical Writing
  • 5.2.6 Patient & Site Recruitment
  • 5.2.7 Safety & Pharmacovigilance
  • 5.2.8 Others (DCT Enablement & eClinical Platforms, Imaging/Core Lab, etc.)
• 5.3 By Device Class
  • 5.3.1 MedTech devices
  • 5.3.2 Diagnostic devices
  • 5.3.3 Handheld devices
  • 5.3.4 Others
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Avania
  • 6.3.2 BSI Group
  • 6.3.3 Charles River Laboratories
  • 6.3.4 ClinChoice
  • 6.3.5 CROMSOURCE
  • 6.3.6 Emergo by UL
  • 6.3.7 Eurofins Scientific
  • 6.3.8 ICON plc
  • 6.3.9 Intertek
  • 6.3.10 IQVIA
  • 6.3.11 Labcorp Drug Development
  • 6.3.12 MCRA
  • 6.3.13 Medpace
  • 6.3.14 NAMSA
  • 6.3.15 Nelson Labs
  • 6.3.16 Parexel
  • 6.3.17 Premier Research
  • 6.3.18 ProPharma Group
  • 6.3.19 Qserve Group
  • 6.3.20 RQM+
  • 6.3.21 SGS
  • 6.3.22 Thermo Fisher Scientific
  • 6.3.23 TUV SUD
  • 6.3.24 Veranex
  • 6.3.25 WuXi AppTec

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment